What is Longiva NAD+ Deaddiction treatment plan?

Chemical dependence, chronic stress related disorders, and neurodegenerative diseases destroy healthy functioning of the brain. Rebalancing the brain requires detoxification and cell function stabilization. At Longiva, we have designed a potent NAD+ formulation and treatment regime to boost NAD+.  Longiva NAD+ is an intravenous protocol that administers a co-enzyme of vitamin B3, along with combinations of amino acids, vitamins and minerals.

This treatment helps the patient nearly or completely free of cravings and withdrawal symptoms. Longiva NAD+ is a natural detox process based upon the patient’s history and needs delivered in an outpatient setting. Our trained nurses under the supervision of a licensed physician administer each treatment. Each patient and their medical needs are different and we take a personalized medicine approach in our NAD Treatment. The treatment plan consists of three phases: 

Phase: 1 Patient Assessment 

Our treatment starts with a thorough assessment of the patient’s physical, emotional and mental health to help us develop a personalized treatment plan, and determine what their protocol will be.  Typical Duration for Assessment Phase: 1 day 

Phase: 2 NAD+ Treatment and Outcome assessment

 Based on the initial patient assessment physician then devise a prescription dosage for NAD+ to be administered intravenously under the supervision of our trained medical staff. Our licensed clinicians work closely with you to manage any symptoms that may arise throughout withdrawal.  If a patient is coming in for addiction treatment, he or she may also be fitted with a device on their first or second day of treatment. The Bridge is an auricular device that helps mitigate withdrawal symptoms within minutes of application and is worn for 5 continuous days. If a patient is coming in for conditions other than drug/alcohol detox, he or she will be assessed on the first or second day of treatment for additional therapies that can help boost the patient’s health to an optimal level. All of our treatments are outpatient in nature.  Throughout the course of treatment, patients may receive additional counseling and alternative therapies that can include everything from emotional and spiritual healing to holistic approaches like yoga, massage, chiropractic care, and much more. At the end of treatment, patients report a great reduction or complete absence of cravings. This type of therapy assists by increasing mental clarity with improved focus, higher energy levels and improvement in mood.  This treatment is not a cure or a substitute for recovery. It is the beginning of your journey towards healing. The underlying issues that led to your substance abuse must still be resolved. Once the brain is restored to optimal functioning, you can stop the self-destructive behavior and better engage in your recovery process. When our treatment is combined with ongoing coaching and counseling, patients are able to make a life-long recovery. Typical Duration for Treatment Phase: 500mg for 7-10 days depending on the personalized treatment needs. An average addiction detox treatment is for 4-6 hr/day for 7-10 days. 

Phase: 3 Follow-up Treatment Plans

 If you’re concerned about the nature of the treatment or the risk of withdrawal, please be reassured in knowing that licensed clinicians are available throughout your treatment to respond to any medical or psychiatric emergencies that could potentially arise. Following treatment, patients will be recommended different treatment plans and recommendations. Our goal is to make sure that each patient’s treatment both in and out of the Longiva NAD Treatment Center is as individualized as possible and that we do everything we can to ensure our patients’ success. If appropriate, the physician also recommends Booster NAD+ treatments that are 1-3 day treatments of NAD+ that are done in addition to the patient’s initial treatment as a follow-up. Typical Duration for Follow-up Phase: 2-6 month follow-ups with periodical patient assessment. 

 Is Longiva NAD+ treatment safe? 

NAD+ is a natural molecule found in all cells of our body. Longiva NAD+ is a safe treatment plan. Our licensed healthcare practitioners work under the supervision of a licensed physician who supervises a customized treatment plan and examination patient responses to the treatment plan.  Literature Cited:

1. Oblong J.E.(2014) The Evovling Role of the NAD+/Nicotinamide Metabolome in Skin Homeostatsis, Cellular Bioenergetics, and Aging DNA Repair(Amst) Apr 29 pii: S1568-7864(14)00116-5. 
2. M.Nakama, Y. Murakami,H Tanaka and S. Nakata (2012) Decrease in nicotinamide Adenine Dinucleotide Dehydrogenase is Related to Skin Pigmentation J. Cosmet Dermatol Mar,11(1):3-8 
3. W. Todd Penberthy, Ikuo Tsunoda. The Importance of NAD in Multiple Sclerosis. Curr Pharm Des. Author manuscript; available in PMC 2009 March 5. Published in final edited form as: Curr Pharm Des. 2009; 15(1): 64–99. 
4. Carles Cantó, Johan Auwerx. Targeting SIRT1 to improve metabolism: all you need is NAD+?. Pharmacol Rev. Author manuscript; available in PMC 2013 April 4. Published in final edited form as: Pharmacol Rev. 2012 January; 64(1): 166–187. Published online 2011 November 21. doi: 10.1124/pr.110.003905 
5. Nagavedi S. Umapathy, Evgeny A. Zemskov, Joyce Gonzales, Boris A. Gorshkov, Supriya Sridhar, Trinad Chakraborty, Rudolf Lucas, Alexander D. Verin. Extracellular β-nicotinamide adenine dinucleotide (β-NAD) promotes the endothelial cell barrier integrity via PKA- and EPAC1/Rac1-dependent actin cytoskeleton rearrangement. J Cell Physiol. Author manuscript; available in PMC 2011 April 1. Published in final edited form as: J Cell Physiol. 2010 April; 223(1): 215–223. 
6. Ziegler M. New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur. J. Biochem. 2000;267:1550–1564.
7. Belenky, P., Racette, F. G., Bogan, K. L., Mcclure, J. M., Smith, J. S., & Brenner, C. (2007). Nicotinamide Riboside Promotes Sir2 Silencing and Extends Lifespan via Nrk and Urh1/Pnp1/Meu1 Pathways to NAD. Cell, 129(3), 473-484. 
8. Imai, S., & Guarente, L. (2014). NAD and sirtuins in aging and disease. Trends in Cell Biology, 24(8), 464-471. 
9. Frederick, D., Loro, E., Liu, L., Davila, A., Chellappa, K., Silverman, I.,Baur, J. (2016). Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle. Cell Metabolism, 24(2), 269-282. 
10. Gomes, A., Price, N., Ling, A., Moslehi, J., Montgomery, M. K., Rajman, L., Sinclair, D. (2013). Declining NAD Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging. Cell, 155(7), 1624-1638. 
11. Prolla, T., & Denu, J. (2014). NAD Deficiency in Age-Related Mitochondrial Dysfunction. Cell Metabolism, 19(2), 178-180. doi:10.1016/j.cmet.2014.01.005
12. Mouchiroud, L., Houtkooper, R. H., & Auwerx, J. (2013). NAD metabolism: A therapeutic target for age-related metabolic disease. Critical Reviews in Biochemistry and Molecular Biology, 48(4), 397-408. 
13. Tran, M. T. et al. PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature 531, 528–532 (2016). 
14. Trammell, S. A. J. et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat. Commun. 7, 12948 (2016). 
15. Pillai, V. B. et al. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3–LKB1–AMP-activated kinase pathway. J. Biol. Chem. 285, 3133–3144 (2010).
16. Zhuo, L. et al. NAD blocks high glucose induced mesangial hypertrophy via activation of the sirtuins–AMPK–mTOR pathway. Cell. Physiol. Biochem. 27, 681–690 (2011). 
17. Zhang, H., NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science  28 Apr 2016:aaf2693 DOI: 10.1126/science.aaf2693
18. N. Braidy,C.K. Lim, R.Grant, B.J. Brew, and G.J. Guillemin(2013) Serum Nicotinamide Adenine Dinucleotide Levels Through Disease Course in Mutiple Sclerosis. Brain Res Nov 6;1537:267-72.) Increasing NAD levels can be important in symptoms and disesae progession. (W.T. Penberthy and I. Tsunoda(2009) The Importance of NAD in Mutiple Sclerosis Curr.Pharm.Des 15(1):64-99)
19. Carles Cantó, Johan Auwerx. Targeting SIRT1 to improve metabolism: all you need is NAD+?. Pharmacol Rev. Author manuscript; available in PMC 2013 April 4. Published in final edited form as: Pharmacol Rev. 2012 January; 64(1): 166–187.